Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012 (2012), Article ID 979154, 5 pages
http://dx.doi.org/10.1155/2012/979154
Clinical Study

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration

1Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan
2Department of Pathology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan

Received 3 March 2011; Accepted 25 April 2011

Academic Editor: Maximilian Burger

Copyright © 2012 Masayoshi Zaitsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. White, “I. The results of double castration in hypertrophy of the prostate,” Annals of Surgery, vol. 22, no. 1, pp. 1–80, 1895. View at Google Scholar
  2. C. Huggins and C. V. Hodges, “Studies on prostate cancer. I . The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate,” Cancer Research, vol. 1, no. 1, pp. 293–297, 1941. View at Google Scholar
  3. U. K. Wenderoth, J. Happ, U. Krause, H. Adenauer, and G. H. Jacobi, “Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients,” European Urology, vol. 8, no. 6, pp. 343–347, 1982. View at Google Scholar · View at Scopus
  4. E. A. Curry III and C. J. Sweeney, “Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer,” Journal of Urology, vol. 168, no. 1, p. 193, 2002. View at Google Scholar · View at Scopus
  5. A. Krongrad, J. Brady, and R. J. Rodriguez, “Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer,” Southern Medical Journal, vol. 90, no. 4, pp. 460–461, 1997. View at Google Scholar · View at Scopus
  6. M. G. Oefelein and R. Cornum, “Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm,” Journal of Urology, vol. 164, no. 3, pp. 726–729, 2000. View at Google Scholar · View at Scopus
  7. G. Novara, A. Galfano, S. Secco, V. Ficarra, and W. Artibani, “Impact of surgical and medical castration on serum testosterone level in prostate cancer patients,” Urologia Internationalis, vol. 82, no. 3, pp. 249–255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Oefelein, A. Feng, M. J. Scolieri, D. Ricchiutti, and M. I. Resnick, “Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making,” Urology, vol. 56, no. 6, pp. 1021–1024, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. E. O. Olapade-Olaopa, A. O. Oluwasola, A. Shonibare, O. A. Falebita, E. E. Akang, and M. T. Shokunbi, “Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy,” South African Medical Journal, vol. 96, no. 9, pp. 810–811, 2006. View at Google Scholar · View at Scopus
  10. L. D. Valle, P. Belvederea, C. Simontacchia, and L. Colombo, “Extraglandular hormonal steroidogenesis in aged rats,” Journal of Steroid Biochemistry and Molecular Biology, vol. 43, no. 8, pp. 1095–1098, 1992. View at Publisher · View at Google Scholar
  11. C. Sievers, J. Klotsche, L. Pieper et al., “Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients,” European Journal of Endocrinology, vol. 163, no. 4, pp. 699–708, 2010. View at Publisher · View at Google Scholar
  12. E. A. Mostaghel, S. T. Page, D. W. Lin et al., “Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer,” Cancer Research, vol. 67, no. 10, pp. 5033–5041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. R. Denmeade and J. T. Isaacs, “Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer,” Prostate, vol. 70, no. 14, pp. 1600–1607, 2010. View at Publisher · View at Google Scholar